Innovating out of Crisis

Transcription

1 Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015

2 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab Laser printers Multifunction copiers on-demand publishing system Document Solutions 1,178.0bil yen 47.2% FY2015/3 Revenue Imaging Solutions 361.0bil yen 14.5% 2,493billion yen Information Solutions 953.6bil yen 38.3% Medical System (medical image, endoscope etc) Recording Media instax Life science Graphic Systems Flat panel display materials (Film for LCD etc) Electronic Materials (semiconductor materials)

3 Fujifilm History In-House Development of Digital Technology with an eye on the arrival of a new age Against the Backdrop of Rapid Digital Technology Development Medical Systems Graphic Systems Imaging Digital Still Camera Digital X-ray Diagnostic Imaging System FCR (Fuji Computed Radiography) Computer to Plate (CTP) CTP Plate Setter Digital Mini Lab Sustaining the photosensitive materials business Creation of New Business Not in photosensitive materials or digital imaging 3

4 Fujifilm History Global Demand Trend of Color Film (Index) Index based on an aggregate demand of 100 in the year Rapid Decline Peak (FY) 4

5 New Growth Strategies Structural reforms New growth strategy Enhancing consolidated management Graphic Arts Systems Digital Imaging Healthcare Capital Investment R&D M&A Investment Document Solutions Optical Devices Highly Functional Materials Six priority business fields

6 New Growth Strategies Fujifilm s Technologies in Four-quadrants Existing Market New Market New Technologies Existing Technologies Is it a growing market? Keys to Determine Priority Businesses Do we have the technology to be applied in this area? Can we stay competitive in this area?

7 History of Healthcare Business X ray FILM foundation 1971 Endoscope wet dry 1981 Digital X-ray diagnostic imaging system (FCR) 1984 Blood diagnosis system (dry-chemistry analyzer ) 1989 IMAGER 1999 PACS (SYNAPSE) Diagnostic nuclear medicine Skincare and supplement products 2008 Acquired Toyama Chemical Business fields Diagnosis Prevention Treatment *1 : Now FUJIFILM Diosynth Biotechnologies, LLC in Texas 2010 Acquired Fujifilm Diosynth Biotechnologies Acquired Kalon *1 Invested in Japan Tissue Engineering 2014 Became consolidated subsidiary 2012 Acquired Fujifilm SonoSite 2015 Acquired Cellular Dynamics International

8 Healthcare Business of Fujifilm Prevention Functional cosmetics Diagnosis X-ray Imaging( FCR/DR/Film) Treatment Low molecule Supplement Endoscopes Radio diagnostic medicines Biopharmaceuticals Haircare Blood analysis systems Regenerative medicine Autologous Cultured Epidermis Autologous Cultured Cartilage

9 Medical System Business X-ray Imaging Diagnostic Equipment Endoscopes Medical IT Ultrasound In Vitro Diagnostics Services

10 Medical System Business Medical IT Delivering diagnostic information quickly, where and when needed, helping hospitals manage information and expenditure. More inflow of clinical data aggregation of valuable data Patient information Electronic medical records CT/MRI IT is centerpiece of information management IVD Regional Partnership Other institutions in the region Ultrasound Endoscopes X-ray

11 Pharmaceutical and Regenerative Medicine Business Low-molecular drugs Biopharmaceuticals Toyama Chemical FUJIFILM Fine Chemicals FUJIFILM Pharma Compound design technology Technological Resources Analysis technology Original nanotechnology FUJIFILM Diosynth Biotechnologies FUJIFILM RI Pharma Perceus Proteomics Regenerative medicine Japan Tissue Engineering Image Diagnosis technology Quality control/high productivity technology Collagen technology FUJIFILM KYOWA KIRIN Biologics Cellular Dynamics International FUJIFILM Drug Discovery Research Laboratory 11

12 Pharmaceutical Business Accelerate R&D for pipeline - Accelerate R&D for pipeline to respond to unmet medical needs, such as cancer FF Anticancer drug (Myelodysplastic syndrome) FF Anticancer drug (Intractable solid cancer) FF Anticancer drug (Intractable solid cancer) Clinical trials in cooperation with MD Anderson Cancer Center T-817MA Alzheimer s disease drug Clinical trials in cooperation with ADCS* / Collaborative research with Kyoto University, Center for ips Cell Research and Application AVIGAN (T-705) Anti-influenza drug Effects on Ebola hemorrhagic fever are expected *Alzheimer s Disease Cooperative Study Accelerate R&D for pipeline by cooperating with leading research organizations and other institutions Differentiate from competitors by creating innovative new drugs with new mechanisms

13 Regenerative Medicine Unmet Medical Needs Age-related macular degeneration Severe heart failure Strokes Spinal Cord Injuries Diabetes Regenerative Medicine Legal Reform ips Cell Technical Advancements Drug Discovery 4

14 For the Sustainable Development of Society Contribute to the development of a sustainable society by creating new value to meet true customers needs and by resolving social issues New medium-term CSR plan Sustainable Value Plan 2016

15